Roof Eidam Maycock Peralta LLC Purchases New Stake in Merck & Co., Inc. $MRK

Roof Eidam Maycock Peralta LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 13,075 shares of the company’s stock, valued at approximately $1,376,000.

Several other hedge funds have also added to or reduced their stakes in MRK. Chemung Canal Trust Co. raised its position in shares of Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after purchasing an additional 13,285 shares during the period. First Pacific Financial raised its position in shares of Merck & Co., Inc. by 14.7% during the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after purchasing an additional 6,082 shares during the period. Diversified Trust Co raised its position in shares of Merck & Co., Inc. by 9.6% during the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after purchasing an additional 18,187 shares during the period. Farther Finance Advisors LLC raised its position in shares of Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after purchasing an additional 32,114 shares during the period. Finally, Coldstream Capital Management Inc. raised its position in shares of Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after purchasing an additional 13,940 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 2.1%

Shares of Merck & Co., Inc. stock opened at $115.42 on Friday. The business’s 50 day simple moving average is $119.18 and its 200 day simple moving average is $105.58. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The firm has a market cap of $285.07 billion, a PE ratio of 15.85, a P/E/G ratio of 2.37 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter last year, the firm earned $1.72 EPS. Merck & Co., Inc.’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: UBS raised its price target on MRK to $145, which is a direct positive signal from a major sell-side firm and can lift investor sentiment. UBS Boosts MRK Price Target
• Positive Sentiment: Zacks highlights Keytruda as the primary growth driver heading into Q1 results, noting new indications and uptake that could sustain revenue growth — this supports medium-term earnings expectations. Will Keytruda Continue to Aid Merck’s Top Line?
• Positive Sentiment: Market chatter and technical traders are bullish on MRK; an options/technical piece highlights a bullish diagonal trade targeting $130, reflecting some traders positioning for a near-term rebound. Bullish Diagonal Trade Targets $130
• Neutral Sentiment: Zacks/Yahoo attention pieces note MRK is a trending stock and recap key facts (pipeline, Keytruda dependence, valuation) — useful for retail interest but not new company-specific catalysts. Merck Is a Trending Stock
• Neutral Sentiment: Industry reports cite Merck among major players in the animal-health market outlook — this is incremental, long-term relevance rather than an immediate stock driver. Animal Health Market Intelligence Report
• Neutral Sentiment: Coverage of Merck KGaA (XTRA:MRK) valuation can create ticker/name confusion for casual readers but has no direct impact on U.S.-listed Merck & Co. fundamentals. Assessing Merck KGaA Valuation
• Neutral Sentiment: Other healthcare staffing and small-cap biotech headlines in the feed (Soleo Health, Summit Therapeutics) are peripheral and unlikely to move MRK stock materially. Soleo Health Appointment Summit Therapeutics BLA Acceptance

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on MRK shares. UBS Group raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup lifted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, March 20th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. TD Cowen lifted their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $128.47.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer directly owned 90,192 shares in the company, valued at $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert M. Davis sold 47,434 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer owned 443,602 shares of the company’s stock, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.